IMNN

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2004, for Celsion Corporation (Note: The input metadata referenced "Imunon, Inc.", but the filing text explicitly identifies the registrant as Celsion Corporation). Celsion is a medical technology company focused on developing products to treat cancer and other diseases using proprietary focused-heat technology. The company recently received FDA premarketing approval for its Prolieve Thermodilatation system for the treatment of Benign Prostatic Hyperplasia (BPH) and began commercialization through a distribution agreement with Boston Scientific Corporation.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Generation: The company recorded sales of $442,945 for the quarter and $542,945 for the six months ended June 30, 2004. There were no product sales in the comparable periods of 2003, as the Prolieve system had not yet received FDA approval or commenced commercialization.
• Operating Expenses:
  • Quarterly Comparison: Total operating expenses decreased by 39% to $1.75 million from $2.85 million in the prior year quarter. This was driven by a 60% reduction in General and Administrative (G&A) expenses and a 28% reduction in R&D expenses, primarily due to lower stock-based compensation costs from repriced options.
  • Six-Month Comparison: Total operating expenses increased slightly by 3% to $7.91 million from $7.65 million. This increase was due to one-time costs including a $972,000 separation agreement, a $350,000 manufacturing termination fee, and $554,000 in cash bonuses, partially offset by reduced stock-based compensation.
• Liquidity: Cash balances increased significantly from $12.27 million at December 31, 2003, to $17.78 million at June 30, 2004. This was fueled by $12.84 million in financing proceeds from stock issuances and warrant exercises, as well as $4 million in licensing fees received from Boston Scientific.

Guidance, Outlook, and Risks

• Outlook: Management anticipates that available cash will fund operations through December 2005. The company expects to expend approximately $12 million in fiscal year 2004 on clinical testing and corporate overhead. Future revenues are expected to come from the Prolieve system, though the timing and amount are unpredictable.
• Capital Needs: The company has no committed sources of additional financing. It may need to raise additional capital through equity or debt offerings, strategic alliances, or other sources. Failure to secure funding could force the company to delay or eliminate operations.
• Risks and Contingencies:
  • Regulatory: The company received an FDA warning letter regarding clinical trials for the Prolieve system (May 2004) and has suspended pivotal Phase II trials for its breast cancer treatment system.
  • Leadership: A search committee was established in May 2004 to recruit a new CEO following the resignation of the previous executive.
  • Escrow Obligations: $2 million of the $4 million licensing fee from Boston Scientific is held in escrow to cover potential claims. Celsion bears full responsibility for claims exceeding escrowed funds.
• Unusual Items: Significant one-time expenses in the first half of 2004 included executive separation costs, manufacturing transition fees, and investment banking fees related to the Boston Scientific agreement.

Investor Verification Checklist

• Verify the status of the FDA warning letter received in May 2004 and the company's response filed in June 2004.
• Confirm the progress of the search for a new Chief Executive Officer.
• Monitor the commercial uptake of the Prolieve system and the performance of the Boston Scientific distribution agreement.
• Review the company's cash burn rate against the projected $12 million expenditure for fiscal 2004 to assess the runway through 2005.
• Assess the impact of the suspended breast cancer trials on the company's long-term pipeline and valuation.